Open AccessThe Relevance of Aurora Kinase Inhibition in Hematological Malignancies
Author(s) -
Caio Bezerra Machado,
Emerson Lucena da Silva,
Beatriz Maria Dias Nogueira,
Jean Breno Silveira Da Silva,
Manoel Odorico de Moraes Filho,
Raquel Carvalho Montenegro,
Maria Elisabete Amaral de Moraes,
Caroline Aquino Moreira-Nunes
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10016
Subject(s) - kinase , aurora inhibitor , clinical trial , aurora kinase , serine , cancer research , protein serine threonine kinases , cell cycle , carcinogenesis , cancer , bioinformatics , medicine , biology , protein kinase a , phosphorylation , microbiology and biotechnology
Aurora kinases are a family of serine/threonine protein kinases that play a central role in eukaryotic cell division. Overexpression of aurora kinases in cancer and their role as major regulators of the cell cycle quickly inspired the idea that their inhibition might be a potential pathway when treating oncologic patients. Over the past couple of decades, the search for designing and testing of molecules capable of inhibiting aurora activities fueled many pre-clinical and clinical studies. In this study, data from the past 10 years of in vitro and in vivo investigations, as well as clinical trials, utilizing aurora kinase inhibitors as therapeutics for hematological malignancies were compiled and discussed, aiming to highlight potential uses of these inhibitors as a novel monotherapy model or alongside conventional chemotherapies. While there is still much to be elucidated, it is clear that these kinases play a key role in oncogenesis, and their manageable toxicity and potentially synergistic effects still render them a focus of interest for future investigations in combinatorial clinical trials.